Form 4: Spyre Therapeutics Director Michael Henderson Reports Share Distribution

Director Michael Henderson reports receiving 105,379 shares of Spyre Therapeutics common stock through a pro-rata distribution from a limited liability company.

Summary

• Michael Henderson, a director of Spyre Therapeutics, Inc., filed a Form 4 on January 14, 2025, reporting a transaction on January 10, 2025.
• The transaction involved the acquisition of 105,379 shares of common stock.
• These shares were received as a pro-rata distribution from a limited liability company where Henderson is a member, with no consideration paid.
• Following the transaction, Henderson beneficially owns 105,379 shares of Spyre Therapeutics common stock.
• Henderson has also granted a Power of Attorney to several individuals, including Ryan Murr and Heidy King-Jones, to execute and file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, indicating a neutral sentiment. It reports a transaction but doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of shares increases Henderson's stake in Spyre Therapeutics, potentially aligning his interests with other shareholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The increased shareholding of a director could be viewed positively by shareholders, signaling confidence in the company's future.

Key Dates